This invention relates to preparation for use against skin tumours and, more especially, this invention relates to a bleomycin preparation for use against skin tumours.
GB-A-2398495 discloses a drug delivery preparation for use against skin tumours. A preferred drug is bleomycin. With the bleomycin preparation disclosed in GB-A-2398495, two related problems have been found to occur. The first problem is providing the bleomycin preparation in a form in which it will remain on the patient's skin for a sufficient period of time to allow the bleomycin in the bleomycin preparation to take effect. For example if the bleomycin preparation is a liquid, then the liquid tends to simply run off the patient's skin and not remain on the patient's skin for the required period of time. The second problem is in providing a bleomycin preparation with a shelf life which is sufficiently long for commercial use requirements.
It is an aim of the present invention to reduce the above mentioned problems.
Accordingly, in one non-limiting embodiment of the present invention there is provided a preparation for use against skin tumours, which preparation has a semi-solid consistency for enabling the preparation to be applied to and remain on a patient's skin during treatment of a tumour on the patient's skin; which preparation comprises bleomycin which acts against the tumour, an elastic liposome which entraps the bleomycin; and a bleomycin containing carrier which contains the bleomycin in the elastic liposome; and which preparation is such that:
The preparation of the present invention is such that its semi-solid consistency enables the preparation to be applied to and remain on the patient's skin for the bleomycin to take effect against the tumour. The preparation has the required shelf life for commercial use due to the above mentioned bleomycin concentrations. For example, the bleomycin preparation of the present invention may have a shelf life of up to one year as compared with a shelf life of 30-40 days of a liquid bleomycin preparation prepared in accordance with the teachings of GB-A-2398495.
The bleomycin containing carrier is preferably present in a concentration of 0.1-100 mg/ml.
Preferably, the bleomycin containing carrier is a bleomycin solution. Other bleomycin carriers may be employed, for example hyaluronic acid, an aqueous cream such as carbapol, or cellulose derivatives.
The bleomycin solution preferably comprises bleomycin in phosphate buffered saline. Other liquids may be employed.
The preparation may be in the form of a cream, ointment, gel or paste.
The bleomycin may be active bleomycin A2 and B2. Alternatively, the bleomycin may be active bleomycin A2. Alternatively the bleomycin may be active bleomycin B2.
The preparation of the present invention may be used for treatment of malignant skin cancers, vulval intraepithelial neoplasia, vulval squamous cell carcinoma, actinic keratoses, keratoacanthomas, kaposi sarcoma, Bowen's disease, and all benign tumours of viral aetiology such for example as human papilloma virus, herpes simplex virus type 8, and molluscum contagiosum.
An embodiment of the invention will now be described solely by way of example and with reference to the accompanying drawings and the following Example.
In the accompanying drawings:
Referring to
A bleomycin preparation was prepared. The bleomycin preparation was a preparation for use against skin tumours. The bleomycin preparation was such that it had a semi-solid consistency for enabling the preparation to be applied to and remain on a patient's skin during treatment of a tumour on the patient's skin. The preparation comprised bleomycin which acts against the tumour, an elastic liposome which entraps the bleomycin; and a Neomycin containing carrier which contains the bleomycin and the elastic liposome. The preparation was such that:
The bleomycin preparation was in the form of a gel. The gel was formed by dissolving the salt of hyaluronic acid or other gelling agents with a equi/hyperosmotic bleomycin solution. The gel was found to have an extended shelf life. The extended shelf life may be up to one year.
The gel was used to treat a patient having skin cancer. The gel was applied twice a day for four weeks. At the end of the treatment, the skin cancer had disappeared.
A bleomycin preparation was prepared for use against skin tumors. The belomycin preparation was such that it had a semi-solid consistency for enabling the preparation to be applied to and remain on the patient's skin during treatment of the tumor on the patient's skin. The preparation comprised belomycin which acts against the tumor, an elastic liposome which entraps the bleomycin, and a bleomycin containing carrier which contains the bleomycin and the elastic liposome. The preparation was such that:
The bleomycin preparation was in the form of a cream/paste. The cream/paste was found to have an extended shelf life. The extended shelf life may be up to one year.
The cream/paste was used to treat a patient having skin cancer. The cream/paste was applied twice a day for four weeks. At the end of the treatment, the skin cancer had disappeared.
Number | Date | Country | Kind |
---|---|---|---|
0623768.9 | Nov 2006 | GB | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/GB2007/004517 | 11/26/2007 | WO | 00 | 10/24/2009 |